TLP
IMDX

Tri Locum Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Tri Locum Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,942
Closed -$12K – 73
2022
Q4 		$12K Buy
+1,942
New +$21.4K ﹤0.01% 72

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Tri Locum Partners's IMDX Position: Q1 2023 in Review

Tri Locum Partners sold out of Insight Molecular Diagnostics (IMDX) in Q1 2023, closing a stake of 1,942 shares — an estimated $12K sold.

Tri Locum Partners first reported a position in IMDX in Q4 2022 and held it in 1 quarter. The position peaked at $12K in Q4 2022. 52 funds tracked by Wall St. Rank hold IMDX as of Q1 2023.

  • Tri Locum Partners reported no remaining Insight Molecular Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 1,942 Insight Molecular Diagnostics shares in Q1 2023, an estimated $12K.
  • Tri Locum Partners first reported a position in Insight Molecular Diagnostics in Q4 2022 and held it in 1 quarter.
  • Tri Locum Partners's Insight Molecular Diagnostics position peaked at $12K in Q4 2022.
  • 52 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.